Apyx Medical Inc

Apyx Medical Inc(APYX)股票分析

$3.060

+0.555 (+18.15%)收盤時

Loading chart…
最高
3.107
開盤
2.600
成交量加權均價
2.91
成交量
995.02K
市值
48.85M
最低
2.575
成交金額
2.90M
企業價值/稅息折舊攤銷前利潤(TTM)
-15.53

Apyx Medical, Inc., formerly Apyx Medical Corporation, is a surgical aesthetics company. Its segments include Advanced Energy and Original Equipment Manufacturer (OEM). The Advanced Energy segment’s product portfolio consists of its Helium Plasma Technology that is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It focuses on the cosmetic surgery market, where Renuvion offers plastic surgeons, facial plastic surgeons and cosmetic physicians the ability to provide controlled heat to the tissue to achieve their desired results. These product lines consist of a multifunction generator, a handpiece and a supply of helium gas. Through OEM agreements, the OEM segment, designs, develops and manufactures electrosurgical equipment and medical devices by producing generators, medical devices and related accessories for medical device manufacturers as well as start-up businesses in need of its energy-based designs.

AI 分析 of Apyx Medical Inc (APYX)

買進

Apyx Medical Corp appears to be a good buy right now, trading at $2.60 with a recent RSI of 56.79, indicating a balanced momentum. The forward P/E ratio is quite high at 72.46, suggesting that while the stock may be overvalued in the short term, the growth potential is significant. The stock has shown a 5.69% increase over the past five days, indicating positive short-term momentum. Furthermore, Maxim Group's buy rating reflects confidence in the company's innovative technology and growth potential, particularly as they raised their revenue guidance for 2026 to between $59 million and $60 million. However, the main risk is the negative net income, which was -$3.24 million in Q2 2026, indicating ongoing losses that investors should monitor closely.

估值指標

Apyx Medical Inc(APYX)目前預期本益比為 72.46,5 年平均預期本益比為 5.82。

預期本益比

嚴重高估
5 年均值 P/E
5.82
目前P/E
72.46
高估
36.80
低估
-25.16

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-9.40
目前EV/EBITDA
-15.53
高估
30.40
低估
-49.21

預期股價營收比

合理
5 年均值 P/S
2.49
目前P/S
1.65
高估
4.41
低估
0.56

Alphio AI 對 APYX 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%APYX

$1.80

情境價格

基

基準

基準 · 50%APYX

$1.74

情境價格

悲

悲觀

悲觀 · 25%APYX

$1.70

情境價格

持有 APYX 的大戶

N

Nantahala Capital Management, LLC

+ 持有APYX

+10.21%

3個月報酬率

事件時間軸

2026-11-05 (ET)

08:31:00

Company Expects Gross Margins of 63% to 65%

08:31:00

AYON Reports Q3 Revenue of $14.03M, 17% Growth

2026-09-29 (ET)

08:30:00

Apyx Medical Releases Renuvion Study Results, Significant Skin Quality Improvement

2026-08-06 (ET)

17:00:00

AYON Reports Q2 Revenue of $13.88M, Beating Expectations

17:00:00

Company Expects Operating Expenses Below $45 Million for 2026

資訊

APYX 常見問題 —— 由 Alphio AI 解答

Apyx Medical, Inc., formerly Apyx Medical Corporation, is a surgical aesthetics company. Its segments include Advanced Energy and Original Equipment Manufacturer (OEM). The Advanced Energy segment’s product portfolio consists of its Helium Plasma Technology that is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It focuses on the cosmetic surgery market, where Renuvion offers plastic surgeons, facial plastic surgeons and cosmetic physicians the ability to provide controlled heat to the tissue to achieve their desired results. These product lines consist of a multifunction generator, a handpiece and a supply of helium gas. Through OEM agreements, the OEM segment, designs, develops and manufactures electrosurgical equipment and medical devices by producing generators, medical devices and related accessories for medical device manufacturers as well as start-up businesses in need of its energy-based designs. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Apyx Medical Corp appears to be a good buy right now, trading at $2.60 with a recent RSI of 56.79, indicating a balanced momentum. The forward P/E ratio is quite high at 72.46, suggesting that while the stock may be overvalued in the short term, the growth potential is significant. The stock has shown a 5.69% increase over the past five days, indicating positive short-term momentum. Furthermore, Maxim Group's buy rating reflects confidence in the company's innovative technology and growth potential, particularly as they raised their revenue guidance for 2026 to between $59 million and $60 million. However, the main risk is the negative net income, which was -$3.24 million in Q2 2026, indicating ongoing losses that investors should monitor closely.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易